CONVERGENT THERAPEUTICS
Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. CONV 01-ฮฑ, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter, was specifical... ly designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV 01-ฮฑ is that, once bound to PSMA, it becomes internalized, thereby delivering its powerful radioactive payload directly into the prostate cancer cells. CONV 01-ฮฑ is covered by multiple issued U.S. and foreign patents. If FDA-approved, CONV 01-ฮฑ would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment.
CONVERGENT THERAPEUTICS
Status:
Active
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Current Employees Featured
Founder
More informations about "Convergent Therapeutics"
Learn About Convergent Therapeutics
World-renowned medical oncologist and scientist. Prior to joining Convergent Therapeutics, Dr. Kantoff spent six years as Chairman of the Department of Medicine at Memorial Sloan โฆSee details»
Convergent Therapeutics - Crunchbase Company โฆ
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer. The company's proprietary technology involves dual-targeted radionuclide therapy developed โฆSee details»
Convergent Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Convergent Therapeutics has received its first shipment of the radioisotope actinium-225 from Cardinal Health to make its Phase 1/2 prostate cancer radiopharmaceutical, according to a โฆSee details»
Convergent Therapeutics, Inc. - The Org
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic โฆSee details»
Convergent Therapeutics, Inc. | LinkedIn
Convergent Therapeutics, Inc. | 2,377 followers on LinkedIn. Developing next-generation targeted combination therapies to advance the care of cancer patients. | Convergent Therapeutics is a ...See details»
NorthStar Medical Radioisotopes and Convergent Therapeutics, โฆ
Aug 13, 2024 About Convergent Therapeutics, Inc. Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing tumor-selective alpha radioantibodies to โฆSee details»
Convergent circles up $90M for cancer โฆ
May 3, 2023 Convergent Therapeutics has circled up $90 million to develop next-gen radiopharmaceuticals in oncology, with its lead clinical program targeting prostate cancer. | Convergent Therapeutics has ...See details»
Convergent Therapeutics gets $90M for radiopharmaceuticals
May 5, 2023 Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today โฆSee details»
Convergent Therapeutics, Inc. - Center For Technology Licensing
Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The companyโs โฆSee details»
Convergent Therapeutics Announces First Patient Treated in
Sep 24, 2024 Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing tumor-selective alpha radioantibodies to target cancer. The company was โฆSee details»
Convergent Therapeutics - Funding, Financials, Valuation & Investors
May 3, 2023 Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer. Search Crunchbase. Start Free Trial . ...See details»
Convergent Therapeutics Announces $90 Million Series A โฆ
May 3, 2023 Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers.See details»
Convergent Therapeutics - VentureRadar
Convergent Therapeutics is a clinical-stage biotechnology company developing targeted radiopharmaceuticals to treat cancer. Radioantibodies precisely target and kill cancer cells โฆSee details»
Convergent Therapeutics - Updates, News, Events, Signals
Dec 11, 2024 PR Newswire โ Convergent Therapeutics Announces First Shipments of Actinium 225 from Cardinal Health to Support the CONVERGE-01 Phase 2 Clinical Trial Funding โฆSee details»
Convergent Therapeutics Announces First Patient Treated in Phase โฆ
CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical โฆSee details»
Convergent Therapeutics - PitchBook
When was Convergent Therapeutics founded? Convergent Therapeutics was founded in 2020. Where is Convergent Therapeutics headquartered? Convergent Therapeutics is โฆSee details»
Convergent Therapeutics Announces First Patient Treated in Phase โฆ
Sep 24, 2024 About Convergent Therapeutics, Inc. Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing tumor-selective alpha radioantibodies to โฆSee details»
Convergent Therapeutics - Craft
Convergent Therapeutics is a biotechnology company that develops radiotherapies for cancer treatment. It offers CONV 01-ฮฑ, a monoclonal antibody conjugated with a radioactive alpha โฆSee details»
Convergent Therapeutics - Contacts, Employees, Board Members, โฆ
Organization. Convergent Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of โฆSee details»
Computational frameworks transform antagonism to synergy in โฆ
1 day ago Basic concepts and role of AI in drug combination prediction. In combination drug therapy, synergy and antagonism are two fundamental concepts that describe the interactions โฆSee details»